{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T03:31:05Z","timestamp":1789011065603,"version":"build-2803163510"},"reference-count":15,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2017,10,1]],"date-time":"2017-10-01T00:00:00Z","timestamp":1506816000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","ejcancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2017,10]]},"DOI":"10.1016\/j.ejca.2017.07.021","type":"journal-article","created":{"date-parts":[[2017,9,4]],"date-time":"2017-09-04T08:00:19Z","timestamp":1504512019000},"page":"149-158","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":21,"special_numbering":"C","title":["Orphan Drug Regulation: A missed opportunity for children and adolescents with cancer"],"prefix":"10.1016","volume":"84","author":[{"given":"Gilles","family":"Vassal","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pam","family":"Kearns","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7318-8986","authenticated-orcid":false,"given":"Patricia","family":"Blanc","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6539-2741","authenticated-orcid":false,"given":"Nicole","family":"Scobie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Delphine","family":"Heenen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andy","family":"Pearson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.ejca.2017.07.021_bib1","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1038\/nrd.2016.80","article-title":"Worldwide collaboration for orphan drug designation","volume":"15","author":"Mariz","year":"2016","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.ejca.2017.07.021_bib2","series-title":"Orphan drug report 2015","author":"Hadjivasilou","year":"2015"},{"issue":"5","key":"10.1016\/j.ejca.2017.07.021_bib3","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1038\/nrd3445","article-title":"European regulation on orphan medicinal products: 10 years of experience and future perspectives","volume":"10","author":"Westermark","year":"2011","journal-title":"Nat Rev Drug Discov"},{"issue":"1","key":"10.1016\/j.ejca.2017.07.021_bib4","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/S1470-2045(13)70548-5","article-title":"Childhood cancer survival in Europe 1999\u20132007: results of EUROCARE-5 \u2013 a population-based study","volume":"15","author":"Gatta","year":"2014","journal-title":"Lancet Oncol"},{"issue":"3","key":"10.1016\/j.ejca.2017.07.021_bib5","doi-asserted-by":"crossref","first-page":"e117","DOI":"10.1016\/S1470-2045(13)70013-5","article-title":"New drugs for children and adolescents with cancer: the need for novel development pathways","volume":"14","author":"Vassal","year":"2013","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ejca.2017.07.021_bib6","unstructured":"Community Register of medicinal products, European Commission http:\/\/ec.europa.eu\/health\/documents\/community-register\/html\/index_en.htm."},{"key":"10.1016\/j.ejca.2017.07.021_bib7","unstructured":"European Medicines Agency Website http:\/\/www.ema.europa.eu\/ema\/index.jsp?curl=pages\/medicines\/landing\/pip_search.jsp."},{"issue":"2","key":"10.1016\/j.ejca.2017.07.021_bib8","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1097\/COC.0000000000000251","article-title":"The Orphan Drug Act: restoring the mission to rare diseases","volume":"39","author":"Daniel","year":"2016","journal-title":"Am J Clin Oncol"},{"issue":"12","key":"10.1016\/j.ejca.2017.07.021_bib9","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.1016\/S1470-2045(13)70467-4","article-title":"Need for change in implementation of paediatric regulation","volume":"14","author":"Vassal","year":"2013","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ejca.2017.07.021_bib10","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1186\/s13023-014-0120-x","article-title":"The influence of the European paediatric regulation on marketing authorisation of orphan drugs for children","volume":"9","author":"Kreeftmeijer-Vegter","year":"2014","journal-title":"Orphanet J Rare Dis"},{"issue":"9","key":"10.1016\/j.ejca.2017.07.021_bib11","doi-asserted-by":"crossref","first-page":"e85971","DOI":"10.1172\/jci.insight.85971","article-title":"Asfotase alfa therapy for children with hypophosphatasia","volume":"1","author":"Whyte","year":"2016","journal-title":"JCI Insight"},{"issue":"6","key":"10.1016\/j.ejca.2017.07.021_bib12","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1158\/1078-0432.CCR-12-2551","article-title":"Is the European paediatric medicine regulation working for children and adolescents with cancer?","volume":"19","author":"Vassal","year":"2013","journal-title":"Clin Cancer Res"},{"issue":"7","key":"10.1016\/j.ejca.2017.07.021_bib13","doi-asserted-by":"crossref","first-page":"e394","DOI":"10.1016\/S1470-2045(17)30442-4","article-title":"From class waivers to precision medicine in paediatric oncology","volume":"18","author":"Pearson","year":"2017","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ejca.2017.07.021_bib14","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.ejca.2016.04.001","article-title":"Implementation of mechanism of action biology-driven early drug development for children with cancer","volume":"62","author":"Pearson","year":"2016","journal-title":"Eur J Cancer"},{"issue":"16","key":"10.1016\/j.ejca.2017.07.021_bib15","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.1001\/jama.2015.11845","article-title":"Experience with the priority review voucher program for drug development","volume":"314","author":"Kesselheim","year":"2015","journal-title":"JAMA"}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804917311413?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804917311413?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,8,28]],"date-time":"2018-08-28T00:05:58Z","timestamp":1535414758000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0959804917311413"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,10]]},"references-count":15,"alternative-id":["S0959804917311413"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2017.07.021","relation":{},"ISSN":["0959-8049"],"issn-type":[{"value":"0959-8049","type":"print"}],"subject":[],"published":{"date-parts":[[2017,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Orphan Drug Regulation: A missed opportunity for children and adolescents with cancer","name":"articletitle","label":"Article Title"},{"value":"European Journal of Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejca.2017.07.021","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}